angiotensin iii

Angiotensin III is an agonist of angiotensin 1 (AT1) and AT2 receptor.

Angiotensin III TFA is an agonist of angiotensin 1 (AT1) and AT2 receptor.

Angiotensin III, human, mouse (TFA), is a peptide hormone involved in blood pressure regulation.

[Val4] Angiotensin III is an angiotensin III peptide variant and a potent full agonist for Gαq and βarr2 signaling pathways, with pEC50 values of 8.31 and 8.44, respectively [1].

Angiotensin III, human is a polypeptide molecule with the sequence RVYIHPF.

Angiotensin III, human, mouse (Angiotensin III, human, mouse(3TFA))(3TFA) is an endogenous angiotensin II receptor (AT2R) agonist(IC50s of 0.648 nM).

Angiotensin Iii(Ile* U-13C6,15N) (Standard) is a reference standard of Angiotensin Iii(Ile* U-13C6,15N) intended for quantitative analysis, quality control, and related biochemical research applications.

Angiotensin I/II (1-6) TFA is a chemical compound comprising amino acids 1-6, derived from the Angiotensin I/II peptide. This peptide is formed by the cleavage of angiotensinogen by renin, with Angiotensin I subsequently hydrolyzed by angiotensin-converting enzyme (ACE) to produce biologically active Angiotensin II. Angiotensin II has been extensively studied for its potential applications in the treatment of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].

Angiotensin I/II (1-5) is a peptide (ASP-ARG-VAL-TYR-ILE) that contains the amino acids 1-5 and is converted from Angiotensin I/II.

Angiotensin I/II (1-6) is a peptide (ASP-ARG-VAL-TYR-ILE-HIS) that contains the amino acids 1-6 and is converted from Angiotensin I/II peptide.

(D-Pro7)-Angiotensin I/II (1-7) is a selective peptide-based antagonist of Angiotensin-(1-7). It effectively blocks various biological effects of Ang-(1-7), inhibits the hypertensive response induced by microinjection of Ang-(1-7) into the rostral ventrolateral medulla (RVLM), and eliminates endothelium-dependent vasorelaxation in mice. This compound is useful in cardiovascular disease research.

Firibastat (RB150) is a glutamyl aminopeptidase antagonist and an orally active brain penetrating prodrug of EC33. It is a first-in-class brain aminopeptidase A (APA) inhibitor with a Ki of 200 nM. Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats[1][2].

Nitrosoglutathione (GSNO) is an endogenous transnitrosation donor involved in S-nitrosation of a variety of cellular proteins. GSNO, an exogenous NO donor and substrate of rat alcohol dehydrogenase class III isoenzyme, inhibits cerebral angiotensin II-dependent and -independent AT1 receptor responses.

Angiotensin II human TFA is a potent vasoconstrictor in the renin-angiotensin system that regulates blood pressure through interactions with AT1R and AT2R receptors. It activates sympathetic nerve activity, promotes aldosterone synthesis and renal function, induces proliferation of vascular smooth muscle cells, and enhances type I and III collagen production in fibroblasts, leading to vascular and myocardial thickening and fibrosis. It also triggers apoptosis and promotes capillary formation, making it suitable for establishing models of cardiac hypertrophy, hypertension, and abdominal aortic aneurysm.

Spinorphin TFA acts as an inhibitor for multiple enkephalin-degrading enzymes, including aminopeptidase (aminopeptidase), dipeptidyl aminopeptidase III (dipeptidyl aminopeptidase III), angiotensin-converting enzyme (angiotensin-converting enzyme), and enkephalinase (enkephalinase). It exhibits an antinociceptive effect [1].